On March 28th, 2025, Fufeng Group Ltd. announced its 2024 Annual Report, showing RMB 27.757 billion of operation revenues in 2024, a year-on-year drop of 0.9%

On March 28th, 2025, CSPC Pharmaceutical Group Ltd. announced its 2024 Annual Report, indicating the operation revenues of RMB 29.009 billion in 2024, a 7.8% decrease from RMB 31.450 billion in 2023.

On March 28th, 2025, North China Pharmaceutical Co., Ltd. announced its 2024 Annual Report, achieving RMB 9,870 million of operation revenues in 2024, down 2.5% year-on-year.

During the 12th week of 2025, inquiries on the Mobaobuy.com surged by 50.7%, with transaction value rising by 48.2% compared to the previous week. The conversion rate climbed to 70.5%

Major Chinese factories have held firm pricing for Threonine, 70% L-Lysine Sulfate, and Methionine, while lowering quotations for 98% L-Lysine HCL.

China’s vitamin market remains sluggish, with most categories experiencing softening prices.

In the European market, different categories are exhibiting varying price dynamics. Prices for Lysine varieties have softened, and Tryptophan prices remain weakly stable. As for Methionine,

In the European market, Vitamins A, E, and D3 were the primary topics of discussion this week.